Event Type
Disclosure
Voluntary
Variant
8-K
Other Events. On November 18, 2025, the Company issued a press release highlighting the promising interim safety profile of LPCN 1154 in our Phase 3 clinical tr
Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed with this report: Exhibit No. Description 99.1 Press Release Highlighting Promi